Condition: Advanced or Metastatic Solid Tumors · Triple Negative Breast Cancer (TNBC) · HR+ Breast Cancer · Sponsor: SHY Therapeutics
This is a Phase 1, first-in-human (FIH), open-label, multicenter study designed to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of SHY-ONC6 in participants with advanced or metastatic solid tumors who have progressed on or are intolerant to standard therapies. The study will consist of 2 parts: a dose escalation part (Phase 1a) and a dose expansion part (Phase 1b).
This description comes directly from the study's public registry record.
Medical Monitor · 619-985-2706 · shyonc6@shytherapeutics.com
Clinical Operations · shyonc6@shytherapeutics.com
Always discuss trial participation with your own doctor first.
| SCRI at HCA HealthONE | Denver, Colorado, United States | Not Yet Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Not Yet Recruiting |
| NEXT Oncology | San Antonio, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07705334